Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

INSYS THERAPEUTICS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Actiq® 400 µg transmucosally
Drug: Fentanyl 400 µg sublingual spray
Drug: Fentanyl citrate injection 100 µg intravenously
Drug: Naltrexone 50 mg

First Posted Date: 2013-01-31

Last Posted Date: 2013-01-31

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT01780233

Locations: 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: Dronabinol Capsules, 5 mg
Drug: Dronabinol Oral Solution

First Posted Date: 2011-10-07

Last Posted Date: 2012-03-26

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 88

Registration Number: NCT01448772

Locations: 🇺🇸
Worldwide Clinical Trials Drug Development Solutions, Austin, Texas, United States

Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: LEP-ETU

First Posted Date: 2010-08-30

Last Posted Date: 2012-08-24

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 70

Registration Number: NCT01190982

Locations: 🇮🇳
Indo-American Cancer Institute and Research Center, Banjara Hills, Hyderabad, India
🇮🇳
P.D. Hinduja Antional Hospital & Medical Research Center, Mahim, Mumbia, India
🇮🇳
Jaslok Hospital and Research Center, Mumbai, India

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Liposome Entrapped Docetaxel (LE-DT)

First Posted Date: 2010-08-25

Last Posted Date: 2018-03-12

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT01188408

Locations: 🇺🇸
Georgetown University Medical center, Washington, District of Columbia, United States
🇺🇸
Providence Portland Medical center, Portland, Oregon, United States

Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Liposome Entrapped Docetaxel (LE-DT)

First Posted Date: 2010-08-23

Last Posted Date: 2012-09-12

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 40

Registration Number: NCT01186731

Locations: 🇺🇸
Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, United States

Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: LE-DT

First Posted Date: 2010-06-28

Last Posted Date: 2011-07-04

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 30

Registration Number: NCT01151384

Locations: 🇺🇸
TGEN/Scottsdale Clinical Research Institute, Scottsdale, Arizona, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Phase 3

Completed

Conditions: Mucositis
Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Fentanyl sublingual spray

First Posted Date: 2009-08-11

Last Posted Date: 2013-09-05

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 18

Registration Number: NCT00956254

Locations: 🇺🇸
InSys Therapeutics, Incorporated, Scottsdale, Arizona, United States

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

Phase 3

Completed

Conditions: Cancer
Pain

Interventions: Drug: Fentanyl sublingual spray

First Posted Date: 2007-10-03

Last Posted Date: 2013-10-11

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 319

Registration Number: NCT00538863

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Phase 3

Completed

Conditions: Cancer

Interventions: Drug: Fentanyl sublingual spray
Drug: Placebo

First Posted Date: 2007-10-03

Last Posted Date: 2014-03-05

Lead Sponsor: INSYS Therapeutics Inc

Target Recruit Count: 130

Registration Number: NCT00538850

Locations: 🇺🇸
InSys Therapeutics, Incorporated, Chandler, Arizona, United States

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Phase 1

Withdrawn

Conditions: Recurrent Malignant Glioma

First Posted Date: 2006-09-19

Last Posted Date: 2014-11-13

Lead Sponsor: INSYS Therapeutics Inc

Registration Number: NCT00378235

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy